Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

Nivolumab 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Cell Non-small Cell Lung Cancer × Nivolumab × Clear all
NCT01642004 2022-12-28

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Bristol-Myers Squibb

Phase 3 Completed
272 enrolled 23 charts
Thoracic

Squamous Cell Non-small Cell Lung Cancer

NCT01721759 2022-06-28

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Bristol-Myers Squibb

Phase 2 Completed
117 enrolled 17 charts
Thoracic

Squamous Cell Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡